Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2011

Polyplus-Transfection Grants Roche Glycart Polyethylenimine License

  • Polyplus-transfection granted Roche Glycart a nonexclusive license to use polyethylenimine (PEI) for in vitro transfection research applications. Roche Glycart will become a Polyplus sublicensee and incorporate the reagent into its R&D of antibody-based products.

    Polyplus reports that its jetPEI transfection reagent is a linear polyethylenimine derivative, free of components of animal origin, and provides effective and reproducible gene delivery into mammalian cells. It can be used in recombinant protein production as well as virus production in cell lines used for protein expression, such as CHO and HEK293. It achieves high DNA transfection with low cytotoxicity, according to the company.

    “We are delighted to sign this license agreement with Roche Glycart AG, an innovative subsidiary of Roche, focused in the research and development of new engineered antibody-based products,” says Mark Bloomfield, CEO of Polyplus-transfection. “PEI-mediated transfection is clearly an essential research tool in this field.”



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »